Monday, April 30, 2007 – 8:30 PM ET

Monday, June 25, 2007 – 8:30 PM ET

Presented by: Steven A. Kaplan, MD;
Moderated by: David Staskin, MD

Presented by: David Staskin, MD;
Moderated by: Norman R. Zinner, MD, MS, FACS

• Define the underlying bladder and/or bladder outlet pathology of lower urinary tract symptoms (LUTS) and overactive bladder (OAB) in men
• Discuss the benefit of urodynamic evaluation and its clinical implication in men with LUTS and OAB
• Recognize up-to-date management strategies in male patients with LUTS and OAB to improve patient outcomes, based on safety considerations

• Describe the pathophysiology of urinary urgency and the challenge to assess this parameter in the urologic patient with OAB
• Discuss warning time, urgency severity and patient-reported outcomes as metrics for urgency

Monday, July 30, 2007 – 8:30 PM ET

Monday, September 10, 2007 – 8:30 PM ET

Presented by: Mary Pat FitzGerald, MD;
Moderated by: David Staskin, MD

Presented by: Alan J. Wein, MD;
Moderated by: David Staskin, MD

• Define the terms associated with nocturnal voiding
• Review the pathophysiology of nocturia and identify the multifactorial risks associated with nocturia
• Discuss the role of pharmacotherapy to alleviate nocturia symptoms and increase patient satisfaction

• Compare patient-reported outcomes instruments to assess symptoms and their severity, health-related quality of life, and treatment satisfaction in patients with overactive bladder
• Discuss how clinical trial data and updated study design can be integrated into clinical practice to improve OAB treatment efficacy

Monday, September 24, 2007 – 8:30 PM ET

Monday, October 29, 2007 – 8:30 PM ET

Presented by: William D. Steers, MD;
Moderated by: David Staskin, MD

Presented by: Scott A. MacDiarmid, MD;
Moderated by: David Staskin, MD

• Review new and established insights into bladder urothelial functioning and its role for signaling and regulatory processes
• Explain muscarinic receptor selectivity in the context of targeted antimuscarinic pharmacotherapy for overactive bladder

• Review the dosing options in available antimuscarinic agents and discuss the potential of flexible dosing for control of overactive bladder symptoms
• Assess the balance between safety and tolerability of antimuscarinics to optimize patient outcomes

The field of urology is rapidly evolving. A proliferation of clinical trials in the field has led to an emergence of new data and changes in the understanding of clinical protocol. In order to offer optimal patient care, practicing urologists and primary care physicians with a special interest in urology need to stay up to date on these new data. To bridge the gap between research and patient care, the Urology Circle offers an online forum for expert opinions and journal reviews. National urology thought leaders provide highlights from recently published peer-reviewed journals. The interactive programs offer and opportunity for the audience to discuss the latest data with national thought leaders during this live web seminar and access previously presented activities at their convenience.

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The Dannemiller Memorial Educational Foundation and The Customer Link, Inc. The Dannemiller Memorial Educational Foundation is accredited by the ACCME to provide continuing medical education for physicians.

The Dannemiller Memorial Educational Foundation designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

This activity is designed for urologists and primary care physicians with a special interest in urology.

This activity will consist of didactic lectures and panel discussions supported by slides posted on the web followed by a question and answer session.

Full faculty disclosure will be provided at the activity.